Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Calidi Biotherapeutics ( (CLDI) ) is now available.
On August 20, 2025, Calidi Biotherapeutics announced an underwritten public offering, raising approximately $6.9 million through the sale of common stock and pre-funded warrant units. The proceeds are intended for working capital, general corporate purposes, and clinical trial preparation. The offering closed on August 21, 2025, with Ladenburg Thalmann & Co. Inc. as the sole book-running manager. This move is expected to bolster Calidi’s financial position and support its ongoing clinical developments, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company based in San Diego, California. It focuses on developing targeted therapies that deliver genetic medicines to distal sites of disease, utilizing its proprietary Redtail platform. The company’s lead candidate targets non-small cell lung cancer, ovarian cancer, and other tumors with high unmet medical needs.
Average Trading Volume: 1,530,785
Technical Sentiment Signal: Sell
Current Market Cap: $8.63M
For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.